These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33022640)

  • 1. Performance Status Restriction in Phase III Cancer Clinical Trials.
    Abi Jaoude J; Kouzy R; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Pasalic D; Verma V; VanderWalde NA; Smith BD; Smith GL; Fuller CD; Das P; Minsky BD; Rödel C; Fokas E; Jagsi R; Thomas CR; Subbiah IM; Taniguchi CM; Ludmir EB
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1322-1326. PubMed ID: 33022640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.
    Ludmir EB; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Mandel JJ; Lin SH; Smith BD; Smith GL; VanderWalde NA; Minsky BD; Koong AC; Stinchcombe TE; Jagsi R; Gomez DR; Thomas CR; Fuller CD
    JAMA Oncol; 2019 Dec; 5(12):1769-1773. PubMed ID: 31158272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis.
    Colloca G
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):232-239. PubMed ID: 34161667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.
    Peters GW; Tao W; Wei W; Miccio JA; Jethwa KR; Cecchini M; Johung KL
    Oncologist; 2021 Aug; 26(8):660-667. PubMed ID: 33728733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials.
    Ludmir EB; Subbiah IM; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Mandel JJ; Fang P; Smith BD; Smith GL; Pinnix CC; Sedrak MS; Kimmick GG; Stinchcombe TE; Jagsi R; Thomas CR; Fuller CD; VanderWalde NA
    J Geriatr Oncol; 2020 Apr; 11(3):451-454. PubMed ID: 31711757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
    BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.
    Tang M; Lee CK; Lewis CR; Boyer M; Brown B; Schaffer A; Pearson SA; Simes RJ
    Lung Cancer; 2022 Apr; 166():40-48. PubMed ID: 35152172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
    Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Diefenhardt M; Das P; Subbiah V; Subbiah IM; Jagsi R; Garden AS; Fokas E; Rödel C; Thomas CR; Minsky BD; Ludmir EB
    Eur J Cancer; 2020 Sep; 136():176-185. PubMed ID: 32702645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
    Spigel DR; McCleod M; Jotte RM; Einhorn L; Horn L; Waterhouse DM; Creelan B; Babu S; Leighl NB; Chandler JC; Couture F; Keogh G; Goss G; Daniel DB; Garon EB; Schwartzberg LS; Sen R; Korytowsky B; Li A; Aanur N; Hussein MA
    J Thorac Oncol; 2019 Sep; 14(9):1628-1639. PubMed ID: 31121324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
    Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
    Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
    Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review.
    Mojsak D; Kuklińska B; Minarowski Ł; Mróz RM
    Adv Med Sci; 2021 Sep; 66(2):381-387. PubMed ID: 34315013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
    Saleh RR; Meti N; Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
    Cancer Med; 2020 Nov; 9(21):7888-7895. PubMed ID: 32886422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
    Giessen C; Graeven U; Laubender RP; Modest DP; Schulz C; Porschen R; Schmiegel W; Reinacher-Schick A; Hegewisch-Becker S; Stintzing S; Heinemann V
    Ann Oncol; 2013 Dec; 24(12):3051-5. PubMed ID: 24130263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research.
    Ebrahimi H; Castro DV; Feng MI; Prajapati SR; Lee KO; Chan EH; Paul T; Sehgal I; Patel J; Li X; Zengin ZB; Meza L; Mercier BD; Hsu J; Govindarajan A; Chawla N; Dizman N; Bergerot CD; Rock A; Liu S; Tripathi A; Dorff T; Pal SK; Chehrazi-Raffle A
    Clin Genitourin Cancer; 2023 Dec; 21(6):e467-e473. PubMed ID: 37301665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
    Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
    Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.